+ Watch VRTX
on My Watchlist
The Company is in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases.
Vertex (VRTX) shares have been halted as an FDA advisory panel will review its telaprevir NDA today7:05 am ET 04/28/2011-Sounds like GOOD NEWS!
-- A Food and Drug Administration advisory panel unanimously recommended approval of Vertex Pharmaceuticals'(VRTX_) proposed hepatitis C drug on Thursday. More on VRTXVertex: FDA Hep C Panel Live BlogTrading Of Vertex Common Stock Halted TodayMerck: FDA Hep C Panel Live BlogMarket ActivityVertex Pharmaceuticals| VRTX UPThe Antiviral Drugs Advisory Committee voted 18-0 to recommend the FDA give a thumbs-up to Vertex's new drug application for telaprevirTrading will resume tomorrow.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions